Well Referenced

Tag: integrative oncology

Complementary cancer therapy: a systematic review of prospective clinical trials on anthroposophic mistletoe extracts

This systematic review analyzed 16 randomized controlled trials (RCTs), 9 non-randomized controlled trials (N-RCTs), and 12 single-arm cohort studies to evaluate the effects of anthroposophic mistletoe extract (Viscum album) in cancer therapy. Of the 17 trials assessing survival, 8 (including 5 of 10 RCTs) reported statistically significant benefits; however, no

Read More »
June 26, 2025 No Comments

Cost-effectiveness of real-world administration of chemotherapy and add-on Viscum album L. therapy compared to chemotherapy in the treatment of stage IV NSCLC patients

This observational study assessed the cost-effectiveness of adding Viscum album L. (mistletoe extract) to standard chemotherapy in patients with stage IV non-small cell lung cancer (NSCLC). Among 118 patients (mean age 63.8, 55.1% male), those receiving Viscum album plus chemotherapy had a longer adjusted mean overall survival (19.1 months) compared

Read More »
June 26, 2025 No Comments

Efficacy and safety of long-term complementary treatment with standardized European mistletoe extract (Viscum album L.) in addition to the conventional adjuvant oncologic therapy in patients with primary non-metastasized mammary carcinoma. Results of a multi-center, comparative, epidemiological cohort study in Germany and Switzerland

This multicenter, retrospective cohort study evaluated the long-term safety and effectiveness of standardized European mistletoe extract (Viscum album L., Iscador) as an adjuvant to conventional oncologic therapy in 1,442 patients with primary non-metastasized breast cancer (UICC stage I–III). Over a median follow-up of 67 months, patients receiving mistletoe extract in

Read More »
June 26, 2025 No Comments

Evaluation of quality of life in lung cancer patients receiving radiation and Viscum album L.: a real-world data study

This 2023 observational study (Radiation Oncology, PMID: 36879290) evaluated 112 lung cancer patients, primarily with non-small-cell lung cancer (median age 70), to assess the impact of adjunctive Viscum album L. (mistletoe) therapy on quality of life (QoL) during standard treatments, including radiation. Over 12 months, patients receiving radiation plus VA

Read More »
June 26, 2025 No Comments

Fever Therapy With Intravenously Applied Mistletoe Extracts for Cancer Patients: A Retrospective Study

This 2017 retrospective observational study (Integrative Cancer Therapies, PMID: 27387685) investigated the safety and immune-stimulating effects of intravenously applied mistletoe extracts (IAMPs) in 59 cancer patients receiving 567 total infusions. Fever (≥38.5°C) was successfully induced in 76% of patients, with an average temperature increase of 1.5°C. Most adverse events were

Read More »
June 26, 2025 No Comments

Five-year Follow-Up of Patients With Early Stage Breast Cancer After a Randomized Study Comparing Additional Treatment With Viscum Album (L.) Extract to Chemotherapy Alone

This 2012 randomized controlled trial (Breast Cancer: Basic and Clinical Research, PMID: 23150723) evaluated the five-year outcomes of adding Viscum album L. (mistletoe extract) to standard chemotherapy in patients with early-stage breast cancer. The study found that patients receiving the combination therapy experienced statistically significant improvements in overall survival and

Read More »
June 26, 2025 No Comments

Impact of Complementary Treatment of Breast Cancer Patients With Standardized Mistletoe Extract During Aftercare: A Controlled Multicenter Comparative Epidemiological Cohort Study

This 2008 multicenter cohort study (Anticancer Research, PMID: 18383896) evaluated the impact of standardized mistletoe extract (HELIXOR) as a complementary therapy in the aftercare of 681 breast cancer patients across 53 hospitals and practices in Germany. Among them, 167 received mistletoe extract, while 514 served as controls. Over approximately five

Read More »
June 26, 2025 No Comments

Impact of Oncological Therapy and Viscum album L Treatment on Cancer-Related Fatigue and Internal Coherence in Nonmetastasized Breast Cancer Patients

This 2020 observational study (Integrative Cancer Therapies, PMID: 32478590) evaluated the impact of add-on Viscum album L. (mistletoe) therapy on cancer-related fatigue, internal coherence, and quality of life in 319 nonmetastasized breast cancer patients over 24 months. While chemotherapy, immunotherapy, and endocrine therapies were associated with worsened fatigue (by 17,

Read More »
June 26, 2025 No Comments

Overall Survival of Nonmetastasized NSCLC Patients Treated With Add-On Viscum album L: A Multicenter Real-World Study

This 2020 multicenter observational study (Integrative Cancer Therapies, PMID: 32856476) evaluated the impact of adding Viscum album L. (mistletoe extract) to standard treatment in 275 patients with nonmetastasized non-small cell lung cancer (NSCLC) stages I–IIIA. Although no significant difference in overall survival (OS) was observed in the full cohort, subgroup

Read More »
June 26, 2025 No Comments

Overall survival of stage IV non-small cell lung cancer patients treated with Viscum album L. in addition to chemotherap

This 2018 multicenter observational study (PLoS ONE, PMID: 30148853) assessed the impact of adding Viscum album L. (mistletoe extract) to standard chemotherapy in 158 patients with stage IV non-small cell lung cancer (NSCLC). Patients who received mistletoe alongside chemotherapy had significantly improved median overall survival (17.0 vs. 8.0 months, p=0.007)

Read More »
June 26, 2025 No Comments